Equillium Inc
Company Profile
Business description
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Contact
2223 Avenida De La Playa
Suite 105
La JollaCA92037
USAT: +1 858 240-1200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
45
Stocks News & Analysis
stocks
Unconventional wisdom: A controversial income pick
stocks
How to avoid dividend disaster
stocks
Why ASX miners will handily beat banks in the long-term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,780.30 | 4.80 | -0.05% |
| CAC 40 | 7,991.52 | 16.10 | -0.20% |
| DAX 40 | 21,874.69 | 27.73 | -0.13% |
| Dow JONES (US) | 44,312.15 | 435.48 | -0.97% |
| FTSE 100 | 8,706.55 | 20.73 | -0.24% |
| HKSE | 21,133.54 | 241.92 | 1.16% |
| NASDAQ | 19,516.87 | 275.12 | -1.39% |
| Nikkei 225 | 38,787.02 | 279.51 | -0.72% |
| NZX 50 Index | 12,902.19 | 57.60 | 0.45% |
| S&P 500 | 6,025.70 | 57.87 | -0.95% |
| S&P/ASX 200 | 8,511.40 | 9.30 | -0.11% |
| SSE Composite Index | 3,303.67 | 33.01 | 1.01% |